Literature DB >> 17266100

HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis.

Miguel A Gonzalez-Gay1, Carlos Gonzalez-Juanatey, Maria J Lopez-Diaz, Angela Piñeiro, Carlos Garcia-Porrua, Jose A Miranda-Filloy, William E R Ollier, Javier Martin, Javier Llorca.   

Abstract

OBJECTIVE: Cardiovascular (CV) disease is the most common cause of mortality in patients with rheumatoid arthritis (RA). We assessed the contribution of epidemiologic features, clinical features, routine laboratory markers of inflammation, and HLA-DRB1 alleles to CV mortality in patients with RA prospectively followed at a single referral center in Spain.
METHODS: Patients fulfilling the 1987 American College of Rheumatology classification criteria for RA seen at the rheumatology outpatient clinic of Hospital Xeral-Calde, Lugo between March and September 1996 were included. HLA-DRB1 phenotype, epidemiologic data, and clinical data were assessed at that time. Patients were prospectively followed and clinical records were examined until patient's death or September 1, 2005.
RESULTS: A total of 182 consecutive patients were assessed. Compared with the general Spanish population, the age- and sex-standardized mortality ratio by CV cause was 1.78. CV mortality adjusted by age at disease onset and sex was associated with chronic inflammation determined by C-reactive protein level (CRP; hazard ratio [HR] 1.14, P < 0.001) and erythrocyte sedimentation rate (ESR; HR 1.05, P = 0.003). Patients with HLA-DRB1*04 shared epitope alleles (HR 4.15, P = 0.030), in particular those HLA-DRB1*0404 positive (HR 6.65, P = 0.002), had increased risk of CV mortality. Increased risk of CV events was also associated with CRP level (HR 1.09, P = 0.001), ESR (HR 1.03, P = 0.003), and HLA-DRB1*0404 (HR 4.47, P = 0.002).
CONCLUSION: Our results suggest that a chronically high inflammatory response in genetically predisposed individuals promotes an increased risk of CV events and CV mortality in RA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266100     DOI: 10.1002/art.22482

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  113 in total

1.  Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity.

Authors:  Baris Yilmazer; Tayfun Sahin; Berrin Öztaş Unlu; Hale Maral Kir; Ayse Cefle
Journal:  Rheumatol Int       Date:  2015-02-11       Impact factor: 2.631

2.  Coronary Artery Calcification and Rheumatoid Arthritis: Lack of Relationship to Risk Alleles for Coronary Artery Disease in the General Population.

Authors:  Iván Ferraz-Amaro; Robert Winchester; Peter K Gregersen; Richard J Reynolds; Mary Chester Wasko; Anette Oeser; Cecilia P Chung; C Michael Stein; Jon T Giles; Joan M Bathon
Journal:  Arthritis Rheumatol       Date:  2017-03       Impact factor: 10.995

3.  Functional capacity in rheumatoid arthritis patients: comparison between Spanish and Brazilian sample.

Authors:  Maiza Ritomy Ide; Miguel A Gonzalez-Gay; Kelly Cristina Yano; Marcelo Jun Imai; Mario Chueire de Andrade; Javier Llorca
Journal:  Rheumatol Int       Date:  2009-12-13       Impact factor: 2.631

Review 4.  Novel risk factors for cardiovascular disease in rheumatoid arthritis.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Ruben-Dario Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 5.  Rheumatoid arthritis and cardiovascular disease.

Authors:  Mary Chester M Wasko
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

Review 6.  Cardiovascular comorbidity in rheumatic diseases.

Authors:  Michael T Nurmohamed; Maaike Heslinga; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

7.  Paradoxical association of C-reactive protein with endothelial function in rheumatoid arthritis.

Authors:  Michael V Holmes; Benyu Jiang; Karen McNeill; Melinda Wong; Stephen P Oakley; Bruce Kirkham; Phil J Chowienczyk
Journal:  PLoS One       Date:  2010-04-27       Impact factor: 3.240

8.  A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis.

Authors:  Rogelio Palomino-Morales; Carlos Gonzalez-Juanatey; Tomas R Vazquez-Rodriguez; Luis Rodriguez; Jose A Miranda-Filloy; Benjamin Fernandez-Gutierrez; Javier Llorca; Javier Martin; Miguel A Gonzalez-Gay
Journal:  Arthritis Res Ther       Date:  2010-04-26       Impact factor: 5.156

9.  Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis.

Authors:  Jonathan Graf; Rebecca Scherzer; Carl Grunfeld; John Imboden
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

10.  Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Holly John; Karen M J Douglas; George D Kitas
Journal:  Arthritis Res Ther       Date:  2009-07-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.